

May 6, 2021



# Artelo Biosciences to Participate at the Benzinga Global Small Cap Conference on May 13, 2021

La Jolla, California--(Newsfile Corp. - May 6, 2021) -[Artelo Biosciences, Inc.](https://www.artelobio.com) (**NASDAQ: ARTL**), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences, is scheduled to present at the Benzinga Global Small Cap Conference at 4:10 PM EST / 1:10 PM PST, on Thursday, May 13, 2021. The Benzinga Global Small Cap Conference will be held from May 13-14, 2021.

Investors interested in joining the Artelo presentation can register for a free spectator pass via the link below: <https://www.benzinga.com/events/small-cap/global/>.

## About the Benzinga Global Small Cap Conference

The Benzinga Global Small Cap Conference bridges the gap between Small Cap companies, investors, and traders. Learn about small cap investing with clearly defined educational modules, take a look at a curated group of small cap investment opportunities, and connect with the global small cap audience in an intimate, virtual setting.

For more information and/or to register for the conference please visit: <https://www.benzinga.com/events/small-cap/global/>.

## About Artelo Biosciences

Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting lipid signaling pathways including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at [www.artelobio.com](https://www.artelobio.com) and Twitter: [@ArteloBio](https://twitter.com/ArteloBio).

## Forward-Looking Statements

*This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to*

*the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.*

**Investor Relations Contact:**

Crescendo Communications, LLC

Tel: 212-671-1020

Email: [ARTL@crescendo-ir.com](mailto:ARTL@crescendo-ir.com)